30 Day Trial

Vericel Reports 3Q16 Revenue

Share:

Vericel posted 3Q16 Carticel revenue of US $8.3MM, +7.8% vs. 3Q15. Carticel is an autologous chondrocyte implant marketed in the U.S. for the treatment of knee cartilage defects.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.